New law enacted by President Lula and two leading cases currently pending before Brazil’s highest courts may leave blockbuster drugs without patent protection in Brazil, say Otto Licks and Marcela de Souza.
Brazil was authorised by the World Trade Organization in 2009 to cross-retaliate against the US for its subsidies on upland cotton. President Lula enacted new legislation, on February 10, 2010, announcing his statutory authority to suspend the rights of US intellectual property owners in Brazil.
Patents on pharmaceutical and chemical products stand out among the targeted IP rights. According to the Brazilian government, although retaliation with goods would certainly bother the US, threatening to lift pharmaceutical patentprotection could make the affected industry sectors push the US government to eliminate its cotton subsidies and negotiate with Brazil. In addition, retaliating against IP rights may benefit local industries and customers, while commercial retaliations could cause the opposite effect, increasing the price of imported products to the Brazilian market.
US companies or citizens who own or license IP rights in Brazil, and even foreign companies located or with their principal place of business in the US, may be affected.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
Brazil, pharmaceutical patents, Brazil, WTO